Arcutis Biotherapeutics Inc (NASDAQ: ARQT) open the trading on Thursday, with great promise as it jumped 0.72% to $8.41, before settling in for the price of $8.35 at the close. Taking a more long-term approach, ARQT posted a 52-week range of $1.76-$13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 303.42%. Meanwhile, its Annual Earning per share during the time was -48.07%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 59.90%. This publicly-traded company’s shares outstanding now amounts to $116.89 million, simultaneously with a float of $101.69 million. The organization now has a market capitalization sitting at $983.04 million. At the time of writing, stock’s 50-day Moving Average stood at $9.73, while the 200-day Moving Average is $9.01.
Arcutis Biotherapeutics Inc (ARQT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Arcutis Biotherapeutics Inc’s current insider ownership accounts for 13.00%, in contrast to 100.10% institutional ownership. According to the most recent insider trade that took place on Oct 01 ’24, this organization’s Director sold 10,000 shares at the rate of 9.26, making the entire transaction reach 92,616 in total value, affecting insider ownership by 181,944. Preceding that transaction, on Oct 02 ’24, Company’s SVP Chief Commercial Officer sold 3,725 for 10.01, making the whole transaction’s value amount to 37,295. This particular insider is now the holder of 136,635 in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
Arcutis Biotherapeutics Inc’s EPS increase for this current 12-month fiscal period is 59.90% and is forecasted to reach -1.14 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 9.80% through the next 5 years, which can be compared against the -48.07% growth it accomplished over the previous five years trading on the market.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Let’s observe the current performance indicators for Arcutis Biotherapeutics Inc (ARQT). It’s Quick Ratio in the last reported quarter now stands at 8.19. The Stock has managed to achieve an average true range (ATR) of 0.56. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.44.
In the same vein, ARQT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.18, a figure that is expected to reach -0.42 in the next quarter, and analysts are predicting that it will be -1.14 at the market close of one year from today.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
[Arcutis Biotherapeutics Inc, ARQT] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 18.30% While, its Average True Range was 0.53.
Raw Stochastic average of Arcutis Biotherapeutics Inc (ARQT) in the period of the previous 100 days is set at 32.72%, which indicates a major rise in contrast to 18.45% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 45.70% that was lower than 69.51% volatility it exhibited in the past 100-days period.
